deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 13-arm NCT01796171

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

A Phase 1/2 Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.

Sponsor: ICON Clinical Research

Conditions Follicular Lymphoma Non-Hodgkin Lymphoma
Interventions 10 MBq/kg Betalutin 100 mg/m2 lilotomab 12.5 mBq/kg Betalutin 15 MBq/kg Betalutin 20 MBq/kg Betalutin 40 mg lilotomab 60 mg/m2 lilotomab Rituximab
Updated 18 times since 2017 Last updated: Jun 19, 2024 Started: Dec 31, 2012 Primary completion: Oct 25, 2022 Completion: Oct 27, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01796171, this PHASE1/PHASE2 trial focuses on Follicular Lymphoma and Non-Hodgkin Lymphoma and remains completed. Sponsored by ICON Clinical Research, it has been updated 18 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Oct 2017 · 9 months · monthly snapshot~Oct 2017 – ~May 2018 · 7 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2022 · 16 months · monthly snapshot~Sep 2022 – ~Feb 2024 · 17 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Sep 2022 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 13 earlier versions

  1. May 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Oct 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  12. Oct 2017 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ICON Clinical Research
  • Nordic Nanovector
Data source: Nordic Nanovector

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Adana, Turkey (Türkiye) , Afula, Israel , Alessandria, Italy , Ankara, Turkey (Türkiye) , Barcelona, Spain , Bergen, Norway , Be’er Ya‘aqov, Israel , Boca Raton, United States , Bologna, Italy and 77 more locations